Components:
Medically reviewed by Oliinyk Elizabeth Ivanovna, PharmD. Last updated on 20.03.2022
Attention! Information on this page is intended only for medical professionals! Information is collected in open sources and may contain significant errors! Be careful and double-check all the information on this page!
Top 20 medicines with the same components:
Pain and associated tension.
Patients with severe liver or kidney complications. Patients with acute intermittent porphyria or with a history of hypersensitivity to Meprobamate (Synaleve Capsules) or any of the active ingredients. Meprobamate (Synaleve Capsules) may induce convulsions in patients with a history of epilepsy.
Contra- indicated in respiratory depression, especially in the presence of cyanosis and excessive bronchial secretion, after operations on the biliary tract, acute alcoholism, head injuries and conditions in which intracranial pressure is raised. It should not be given during an attack of bronchial asthma or in heart failure secondary to chronic lung disease.
Contra-indicated in patients taking monoamine oxidase inhibitors or within fourteen days of stopping such treatment.
Side-effects of paracetamol are usually mild, though haematological reactions have been reported. Dosage in excess of those recommended may cause severe liver damage. Sensitivity reactions resulting in reversible skin rash or blood disorders may occur, but these are rare. Patients suffering from liver or kidney disease should take paracetamol under medical supervision. Consult your doctor if no relief is obtained from the recommended dosage.
In normal doses the more common side-effects of Codeine (Synaleve Capsules) phosphate are constipation, nausea and vomiting, dizziness and drowsiness. Dry mouth, facial flushing, vertigo, bradycardia, palpitations, faintness, sedation, restlessness, changes of mood, and miosis may also occur. These effects occur more commonly in ambulant patients than in those at rest in bed. Raised intracranial pressure occurs in some patients. Orthostatic hypotension, hypothermia and difficulty in micturition may occur.
Codeine (Synaleve Capsules) should be given with caution to patients with hypothyroidism, adrenocortical insufficiency, impaired liver function, prostatic hypertrophy or shock. It should be used with caution in patients with inflammatory or obstructive bowel disorders. The dosage should be reduced in elderly and debilitated patients.
The depressant effects of Codeine (Synaleve Capsules) are enhanced by depressants of the central nervous system such as alcohol, anaesthetics, hypnotics and sedatives, and phenothiazines.
The prolonged use of high doses of Codeine (Synaleve Capsules) has produced dependence of the morphine type.
Due to the histamine-releasing effect allergic reactions such as urticaria pruritus, and itching of the nose occur in some individuals and idiosyncrasy to Codeine (Synaleve Capsules) and other narcotic analgesics is fairly common.
Drowsiness is the most frequent side-effect of Meprobamate (Synaleve Capsules). Other effects include nausea, vomiting, diarrhoea, paraesthesia, weakness, and central effects such as headache, excitement, dizziness, ataxia and disturbances of vision. There may be hypotension, tachycardia, and cardiac arrhythmias.
The use of this medicine may cause drowsiness and care should be taken when driving or operating machinery. Reduce dosage if necessary.
Patients receiving Meprobamate (Synaleve Capsules) should be warned that their tolerance to ingested alcohol and other depressants of the central nervous system may be lowered with consequent impairment of judgement and co-ordination.
Hypersensitivity reactions may occur. These may be limited to skin rashes, urticaria and purpura or may be more severe with angioneurotic oedema, bronchospasm or anuria. Erythema multiforme has been reported. Treatment should be discontinued as soon as these reactions occur. Blood disorders including agranulocytosis, eosinophilia, leucopenia, thrombocytopenia, and aplastic anaemia have been reported. Symptoms of porphyria may be exacerbated. There is a serious dependence risk with a typical withdrawal syndrome. Meprobamate (Synaleve Capsules) may induce the hepatic microsomal enzymes involved in medicine metabolism.